Aelis Farma SA (EPA:AELIS)

Market Cap	15.50M
Revenue (ttm)	5.56M
Net Income (ttm)	-7.46M
Shares Out	13.59M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,097
Average Volume	33,740
Open	1.190
Previous Close	1.140
Day's Range	1.160 - 1.390
52-Week Range	0.672 - 5.550
Beta	0.46
RSI	47.67
Earnings Date	Sep 22, 2025

About Aelis Farma

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive imp...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 28
• Stock Exchange: Euronext Paris
• Ticker Symbol: AELIS

Financial Performance

In 2024, Aelis Farma's revenue was 5.56 million, a decrease of -54.99% compared to the previous year's 12.36 million. Losses were -7.46 million, 46.8% more than in 2023.